Karijn P.M. Suijkerbuijk

Author

Also Known As

Femke van Wijk, J Derksen, K P M Suijkerbuijk, K Suijkerbuijk, K. P. M. Suijkerbuijk, K. Suijkerbuijk, K.P. Suijkerbuijk, K.P.M. Suijkerbuijk, Karijn P.M. Suijkerbuijk, Karijn P M Suijkerbuijk

266

Publications

8.3K

Citations

H-Index

Concepts

All Affiliations

University Medical Center Utrecht The Netherlands Cancer Institute Leiden University Medical Center University Medical Center Groningen Isala

About

Karijn P.M. Suijkerbuijk is an author at University Medical Center Utrecht specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	28	4.5K
2	Health Sciences	7	7	179
3	Cell Biology	2	2	202
4	Natural Sciences	1	1	128
5	Public Health	1	1	77

Karijn P.M. Suijkerbuijk

Publications

7.2K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Barbara Burtness, Kevin J. Harrington, Richard Greil, The Lancet Neoadjuvant TherapyChemotherapy Versus CetuximabMedicinePathologyHead And Neck Cancer	2019	3K
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma Maartje W. Rohaan, Troels Holz Borch, Joost H. van den Berg, New England Journal of Medicine	2022	474
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial Irene L. M. Reijers, Alexander M. Menzies, Alexander C. J. van Akkooi, Nature Medicine Surgical OncologyOncologyPrado TrialMelanomaClinical Trials	2022	322
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis James Larkin, Bartosz Chmielowski, Christopher D. Lao, The Oncologist	2017	257
ESMO Guidance for Reporting Oncology real-World evidence (GROW) Luís Castelo-Branco, Anna Pellat, Diogo Martins-Branco, Annals of Oncology MedicineCancer ManagementCancer RegistrationEsmo GuidanceOncology	2023	183
The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2α Eelke Gort, Gijs van Haaften, Ingrid Verlaan, Oncogene Redox RegulatorNatural SciencesHypoxia (Medicine)Molecular BiologyTwist1 Oncogene	2007	128
Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations Christian Menzer, Alexander M. Menzies, Matteo S. Carlino, Journal of Clinical Oncology	2019	122
Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease Monique K. van der Kooij, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Annals of Internal Medicine	2021	103
Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma Olivier J. van Not, Rik J. Verheijden, Alfonsus Johannes Maria van den Eertwegh, JAMA Oncology	2022	99
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Teresa Amaral, Margaret Ottaviano, Ana Arance, Annals of Oncology Dermoscopic ImageMelanomaCutaneous MelanomaDermatologyRadiation Oncology	2024	99

Page 1